Phenylephrine/ketorolac

From Wikipedia, the free encyclopedia

Phenylephrine/ketorolac
Combination of
PhenylephrineAlpha-1 adrenergic receptor agonist
KetorolacNonsteroidal anti-inflammatory
Clinical data
Trade namesOmidria
AHFS/Drugs.comMonograph
License data
Routes of
administration
Intraocular
ATC code
Legal status
Legal status
  • US: ℞-only [1]
  • EU: Rx-only [2]
  • In general: ℞ (Prescription only)
Identifiers
KEGG

Phenylephrine/ketorolac, sold under the brand name Omidria, is a combination drug used during cataract surgery[3] or intraocular lens replacement to prevent intraoperative miosis and to reduce postoperative pain.[1] It contains phenylephrine and ketorolac.[1]

Phenylephrine/ketorolac was approved for medical use in the United States in May 2014,[4] and in the European Union in July 2015.[2]

References[edit]

  1. ^ a b c "Omidria- phenylephrine and ketorolac injection, solution, concentrate". DailyMed. 11 December 2017. Retrieved 17 April 2020.
  2. ^ a b "Omidria EPAR". European Medicines Agency (EMA). Retrieved 17 April 2020.
  3. ^ Lawuyi LE, Gurbaxani A (2015). "The clinical utility of new combination phenylephrine/ketorolac injection in cataract surgery". Clinical Ophthalmology. Auckland, N.Z. 9: 1249–54. doi:10.2147/OPTH.S72321. PMC 4506037. PMID 26203214.
  4. ^ "Drug Approval Package: Omidria (phenylephrine and ketorolac) Injection NDA #205388". U.S. Food and Drug Administration (FDA). 9 December 2014. Retrieved 17 April 2020.

External links[edit]